Clinical Trials
158 trialsNCT03998254 2026-06-02
V503-023
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06959563 2026-05-20
9vHPV-BCG
Medicine Invention Design, Inc
Phase EARLY_PHASE1 Active not recruiting
NCT07572396 2026-05-14
Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
Amplexd Therapeutics, Inc.
Phase 2 Recruiting
NCT03903562 2026-04-06
V503-024
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06491446 2026-02-18
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Antiva Biosciences
Phase 1/2 Active not recruiting
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07281599 2026-02-02
EQUIP
Qurasense
Phase NA Recruiting
NCT06632912 2026-01-23
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
National Vaccine and Serum Institute, China
Phase 3 Active not recruiting
NCT05262010 2026-01-16
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China
Phase 3 Recruiting
NCT04210336 2025-12-18
PAPILOCAN
Procare Health Iberia S.L.
Phase NA Completed
NCT06756269 2025-12-17
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT06538480 2025-12-15
Zopa Retreatment and Vector Shedding in Adults With RRP
Precigen, Inc
Phase 4 Recruiting
NCT06285357 2025-11-20
The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
Lo.Li.Pharma s.r.l
Phase NA Recruiting
NCT04098744 2025-10-02
ART-CIN_IIB
Frantz Viral Therapeutics, LLC
Phase 2 Recruiting
NCT04607850 2025-08-28
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
Barinthus Biotherapeutics
Phase 1/2 Completed
NCT06075264 2025-08-14
ART-VIN IIB
Frantz Viral Therapeutics, LLC
Phase 2 Recruiting
NCT06120205 2025-07-18
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
Teal Health, Inc.
Phase NA Active not recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04724980 2025-06-11
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Precigen, Inc
Phase 1/2 Active not recruiting
NCT04772534 2025-05-30
V503-066
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05555862 2025-05-18
anal HSIL HIV-
Frantz Viral Therapeutics, LLC
Phase 2 Active not recruiting
NCT04708041 2025-04-20
V503-069
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00733122 2025-03-03
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT05829629 2025-02-14
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
BlueSky Immunotherapies GmbH
Phase 1 Recruiting
NCT03610581 2025-02-04
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
Janssen Vaccines & Prevention B.V.
Phase 1/2 Terminated
NCT06797986 2025-01-29
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
Cellid Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06281119 2025-01-07
Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years
Serum Institute of India Pvt. Ltd.
Phase 3 Not yet recruiting
NCT06454175 2025-01-06
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Active not recruiting
NCT05285826 2024-12-16
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT06672653 2024-11-04
PREPAP
MGB Pharma
Phase 1/2 Not yet recruiting
NCT04199078 2024-10-31
PALOMA2
Procare Health Iberia S.L.
Phase NA Completed
NCT04472377 2024-10-03
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc.
Phase NA Completed
NCT06439433 2024-06-03
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT04895020 2024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Unknown
NCT05027776 2024-04-17
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05916911 2024-02-07
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
Catalysis SL
Phase 4 Unknown
NCT06207175 2024-01-23
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT03912831 2023-12-26
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Phase 1 Terminated
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT06111911 2023-11-01
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)
PT Bio Farma
Phase NA Completed
NCT06041061 2023-09-18
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
Sinocelltech Ltd.
Phase 3 Active not recruiting
NCT04490512 2023-06-26
Study of FluBHPVE6E7 in HPV-16 Infected Women
BlueSky Immunotherapies GmbH
Phase 1 Completed
NCT00380367 2023-05-31
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT04965350 2023-04-13
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed